Trait: female reproductive organ cancer

Trait Information
Identifier MONDO_0001416
Description A primary or metastatic malignant neoplasm involving the female reproductive system. Representative examples include endometrial carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus leiomyosarcoma, adenosarcoma, malignant mixed mesodermal (mullerian) tumor, and gestational choriocarcinoma. [NCIT: C4913]
Trait category
Other trait
Synonyms 18 synonyms
  • cancer of female reproductive organ
  • female reproductive cancer
  • female reproductive organ cancer
  • gynecologic cancer
  • malignant female reproductive organ neoplasm
  • malignant female reproductive system neoplasm
  • malignant female reproductive system tumor
  • malignant female reproductive system tumour
  • malignant gynecologic neoplasm
  • malignant gynecologic tumor
  • malignant gynecologic tumour
  • malignant neoplasm of female reproductive organ
  • malignant neoplasm of female reproductive system
  • malignant neoplasm of the female reproductive system
  • malignant tumor of female reproductive system
  • malignant tumor of the female reproductive system
  • malignant tumour of female reproductive system
  • malignant tumour of the female reproductive system
Child trait(s) 10 child traits

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported
Note: This table shows PGS for child terms of "female reproductive organ cancer" in the EFO hierarchy.
Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution
GWAS
Dev
Eval
 Scoring File (FTP Link)
PGS000048
(OCPRS_Overall)
 PGP000033 |
Kuchenbaecker KB et al. J Natl Cancer Inst (2017)
 Ovarian cancer ovarian carcinoma 17
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000048/ScoringFiles/PGS000048.txt.gz
PGS000068
(PRS_EOC)
 PGP000048 |
Yang X et al. J Med Genet (2018)
 Epithelial ovarian cancer ovarian carcinoma 15
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000068/ScoringFiles/PGS000068.txt.gz
PGS000069
(PRS_sEOC)
 PGP000048 |
Yang X et al. J Med Genet (2018)
 Serous epithelial ovarian cancer ovarian serous carcinoma 15
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000069/ScoringFiles/PGS000069.txt.gz
PGS000073
(CC_Cervix)
 PGP000050 |
Graff RE et al. Nat Commun (2021)
 Cervical cancer cervical carcinoma 10
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000073/ScoringFiles/PGS000073.txt.gz
PGS000075
(CC_Endo)
 PGP000050 |
Graff RE et al. Nat Commun (2021)
 Endometrial cancer endometrial carcinoma 9
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000075/ScoringFiles/PGS000075.txt.gz
PGS000082
(CC_Ovary)
 PGP000050 |
Graff RE et al. Nat Commun (2021)
 Ovarian cancer ovarian carcinoma 36
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000082/ScoringFiles/PGS000082.txt.gz
PGS000158
(cGRS_Ovarian)
 PGP000075 |
Shi Z et al. Cancer Med (2019)
 Ovarian cancer ovarian carcinoma 11
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000158/ScoringFiles/PGS000158.txt.gz
PGS000351
(PRS_EOC)
 PGP000117 |
Barnes DR et al. Genet Med (2020)
 Invasive epithelial ovarian cancer ovarian carcinoma 30
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000351/ScoringFiles/PGS000351.txt.gz
PGS000352
(PRS_HGS)
 PGP000117 |
Barnes DR et al. Genet Med (2020)
 High grade serous ovarian cancer high grade ovarian serous adenocarcinoma 22
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000352/ScoringFiles/PGS000352.txt.gz
PGS000541
(PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_P_5e-08_UKB_20200608)
 PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
 Malignant neoplasm of uterus uterine cancer 18
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000541/ScoringFiles/PGS000541.txt.gz
PGS000542
(PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_PT_UKB_20200608)
 PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
 Malignant neoplasm of uterus uterine cancer 20
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000542/ScoringFiles/PGS000542.txt.gz
PGS000724
(PRS_Ovary)
 PGP000135 |
Jia G et al. JNCI Cancer Spectr (2020)
 Epithelial ovarian cancer ovarian carcinoma 31
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000724/ScoringFiles/PGS000724.txt.gz
PGS000784
(CC_Cervix_IV)
 PGP000186 |
Kachuri L et al. Nat Commun (2020)
 Cervical cancer cervical carcinoma 10
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000784/ScoringFiles/PGS000784.txt.gz
PGS000786
(CC_Endo_IV)
 PGP000186 |
Kachuri L et al. Nat Commun (2020)
 Endometrial cancer endometrial carcinoma 9
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000786/ScoringFiles/PGS000786.txt.gz
PGS000793
(CC_Ovary_IV)
 PGP000186 |
Kachuri L et al. Nat Commun (2020)
 Ovarian cancer ovarian carcinoma 36
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000793/ScoringFiles/PGS000793.txt.gz
PGS001299
(GBE_cancer1041)
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Cervical cancer cervical carcinoma 24
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001299/ScoringFiles/PGS001299.txt.gz
PGS001795
(1kgeur_gbmi_leaveUKBBout_UtC_pst_eff_a1_b0.5_phiauto)
 PGP000262 |
Wang Y et al. Cell Genom (2023)
 Uterine cancer uterine carcinoma 911,692
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001795/ScoringFiles/PGS001795.txt.gz
PGS002250
(PRS_S4)
 PGP000277 |
Dareng EO et al. Eur J Hum Genet (2022)
 Epithelial ovarian cancer ovarian carcinoma 27,240
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002250/ScoringFiles/PGS002250.txt.gz
PGS002300
(PRS19_endometrial)
 PGP000328 |
Choi J et al. Int J Cancer (2020)
 Endometrial cancer endometrial cancer 19
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002300/ScoringFiles/PGS002300.txt.gz
PGS002735
(PRS19)
 PGP000344 |
Bafligil C et al. Genet Med (2022)
 Endometrial cancer endometrial carcinoma 19
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002735/ScoringFiles/PGS002735.txt.gz
PGS002736
(PRS24)
 PGP000344 |
Bafligil C et al. Genet Med (2022)
 Endometrial cancer endometrial carcinoma 24
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002736/ScoringFiles/PGS002736.txt.gz
PGS002737
(PRS72)
 PGP000344 |
Bafligil C et al. Genet Med (2022)
 Endometrial cancer endometrial carcinoma 72
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002737/ScoringFiles/PGS002737.txt.gz
PGS003381
(best_UCEC)
 PGP000413 |
Namba S et al. Cancer Res (2022)
 Uterine endometrial carcinoma endometrial carcinoma 529,365
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003381/ScoringFiles/PGS003381.txt.gz
PGS003385
(best_OV)
 PGP000413 |
Namba S et al. Cancer Res (2022)
 Ovarian serous carcinoma ovarian serous carcinoma 144,810
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003385/ScoringFiles/PGS003385.txt.gz
PGS003389
(best_CESC)
 PGP000413 |
Namba S et al. Cancer Res (2022)
 Cervical cancer cervical carcinoma 2,814
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003389/ScoringFiles/PGS003389.txt.gz
PGS003394
(PRS_Stepwise)
 PGP000277 |
Dareng EO et al. Eur J Hum Genet (2022)
 Epithelial ovarian cancer ovarian carcinoma 36
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003394/ScoringFiles/PGS003394.txt.gz
PGS003428
(Ldpred_CC_170223)
 PGP000435 |
Koel M et al. Hum Mol Genet (2023)
 Cervical cancer cervical carcinoma 2,894,555
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003428/ScoringFiles/PGS003428.txt.gz
PGS003740
(PRS16_CU)
 PGP000470 |
Xin J et al. EBioMedicine (2023)
 Corpus Uteri uterine corpus cancer 16
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003740/ScoringFiles/PGS003740.txt.gz
PGS003741
(PRS28_OC)
 PGP000470 |
Xin J et al. EBioMedicine (2023)
 Ovarian cancer ovarian carcinoma 28
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003741/ScoringFiles/PGS003741.txt.gz
PGS003754
(PRS22_OCstepwise)
 PGP000474 |
Hurwitz LM et al. JAMA Netw Open (2023)
 Nonmucinous Epithelial Ovarian Cancer ovarian carcinoma 22
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003754/ScoringFiles/PGS003754.txt.gz
PGS004244
(PRS16_endometrium)
 PGP000542 |
Kim ES et al. NPJ Precis Oncol (2023)
 Endometrial cancer endometrial carcinoma 16
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004244/ScoringFiles/PGS004244.txt.gz
PGS004249
(PRS25_ovary)
 PGP000542 |
Kim ES et al. NPJ Precis Oncol (2023)
 Ovarian cancer ovarian carcinoma 25
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004249/ScoringFiles/PGS004249.txt.gz
PGS004692
(ovarian_cancer)
 PGP000596 |
Hu J et al. JNCI Cancer Spectr (2024)
 Ovarian cancer ovarian carcinoma 6,385,666
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004692/ScoringFiles/PGS004692.txt.gz
PGS005086
(PGS64518_OC)
 PGP000680 |
Barnes DR et al. NPJ Genom Med (2025)
 Non-mucinous epithelial ovarian cancer ovarian carcinoma 64,518
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005086/ScoringFiles/PGS005086.txt.gz
PGS005087
(PGS5957_OC)
 PGP000680 |
Barnes DR et al. NPJ Genom Med (2025)
 Non-mucinous epithelial ovarian cancer ovarian carcinoma 5,957
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005087/ScoringFiles/PGS005087.txt.gz
PGS005088
(PGS3448_OC)
 PGP000680 |
Barnes DR et al. NPJ Genom Med (2025)
 Non-mucinous epithelial ovarian cancer ovarian carcinoma 3,448
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005088/ScoringFiles/PGS005088.txt.gz
PGS005089
(PGS400_OC)
 PGP000680 |
Barnes DR et al. NPJ Genom Med (2025)
 Non-mucinous epithelial ovarian cancer ovarian carcinoma 400
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005089/ScoringFiles/PGS005089.txt.gz
PGS005165
(PRS-CC)
 PGP000711 |
Zhu M et al. PLoS Med (2025)
 Cervical cancer cervical carcinoma 15
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005165/ScoringFiles/PGS005165.txt.gz
PGS005166
(PRS-OC)
 PGP000711 |
Zhu M et al. PLoS Med (2025)
 Ovarian cancer ovarian carcinoma 2,802
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005166/ScoringFiles/PGS005166.txt.gz
PGS018540
(TPMI_180_Lassosum2)
 PGP000835 |
Chen HH et al. Nature (2025)
 Cervical cancer and dysplasia cervical cancer 32
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS018540/ScoringFiles/PGS018540.txt.gz
PGS018541
(TPMI_180_LDpred2)
 PGP000835 |
Chen HH et al. Nature (2025)
 Cervical cancer and dysplasia cervical cancer 939,805
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS018541/ScoringFiles/PGS018541.txt.gz
PGS018542
(TPMI_180_MegaPRS)
 PGP000835 |
Chen HH et al. Nature (2025)
 Cervical cancer and dysplasia cervical cancer 16,145
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS018542/ScoringFiles/PGS018542.txt.gz
PGS018543
(TPMI_180_PRS-CS)
 PGP000835 |
Chen HH et al. Nature (2025)
 Cervical cancer and dysplasia cervical cancer 983,767
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS018543/ScoringFiles/PGS018543.txt.gz
PGS018544
(TPMI_180_SBayesR)
 PGP000835 |
Chen HH et al. Nature (2025)
 Cervical cancer and dysplasia cervical cancer 992,634
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS018544/ScoringFiles/PGS018544.txt.gz
PGS018545
(TPMI_180.1_Lassosum2)
 PGP000835 |
Chen HH et al. Nature (2025)
 Cervical cancer cervical cancer 1,050
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS018545/ScoringFiles/PGS018545.txt.gz
PGS018546
(TPMI_180.1_LDpred2)
 PGP000835 |
Chen HH et al. Nature (2025)
 Cervical cancer cervical cancer 280,778
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS018546/ScoringFiles/PGS018546.txt.gz
PGS018547
(TPMI_180.1_MegaPRS)
 PGP000835 |
Chen HH et al. Nature (2025)
 Cervical cancer cervical cancer 540,580
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS018547/ScoringFiles/PGS018547.txt.gz
PGS018548
(TPMI_180.1_PRS-CS)
 PGP000835 |
Chen HH et al. Nature (2025)
 Cervical cancer cervical cancer 983,768
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS018548/ScoringFiles/PGS018548.txt.gz
PGS018549
(TPMI_180.1_SBayesR)
 PGP000835 |
Chen HH et al. Nature (2025)
 Cervical cancer cervical cancer 1,011,318
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS018549/ScoringFiles/PGS018549.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		Evaluated Score PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM000112 PGS000048
(OCPRS_Overall)
 PSS000072|
European Ancestry|
15,252 individuals
 PGP000033 |
Kuchenbaecker KB et al. J Natl Cancer Inst (2017)
 Reported Trait: Ovarian cancer in BRCA1 mutation carriers HR: 1.28 [1.22, 1.34] C-index: 0.579 [0.559, 0.6] — Country, birth year —
PPM000113 PGS000048
(OCPRS_Overall)
 PSS000073|
European Ancestry|
8,211 individuals
 PGP000033 |
Kuchenbaecker KB et al. J Natl Cancer Inst (2017)
 Reported Trait: Ovarian cancer in BRCA2 mutation carriers HR: 1.49 [1.34, 1.65] C-index: 0.628 [0.592, 0.665] — Country, birth year —
PPM000188 PGS000068
(PRS_EOC)
 PSS000108|
European Ancestry|
4,095 individuals
 PGP000048 |
Yang X et al. J Med Genet (2018)
 Reported Trait: all invasive epithelial ovarian cancer OR: 1.32 [1.21, 1.45] C-index: 0.58 [0.55, 0.6] — — —
PPM000189 PGS000069
(PRS_sEOC)
 PSS000108|
European Ancestry|
4,095 individuals
 PGP000048 |
Yang X et al. J Med Genet (2018)
 Reported Trait: serous epithelial ovarian cancer OR: 1.43 [1.29, 1.58] C-index: 0.6 [0.57, 0.63] — — —
PPM000193 PGS000073
(CC_Cervix)
 PSS000112|
European Ancestry|
226,216 individuals
 PGP000050 |
Graff RE et al. Nat Commun (2021)
 Reported Trait: Cervical cancer OR: 1.22 [1.19, 1.25] — — Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. Results from meta-analysis of GERA and UKB
PPM002039 PGS000073
(CC_Cervix)
 PSS001012|
European Ancestry|
211,795 individuals
 PGP000186 |
Kachuri L et al. Nat Commun (2020)
|Ext.		 Reported Trait: Incident cervical cancer HR: 1.22 [1.09, 1.37] AUROC: 0.745
C-index: 0.75 (0.017)		 — Age at assessment, genotyping array, PCs(1-15), parity ( ≥1 live birth vs. none), oral contraceptive use (never used (0) vs. <20 years vs. ≥20 years), cigarette pack-years C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years.
PPM000195 PGS000075
(CC_Endo)
 PSS000114|
European Ancestry|
221,699 individuals
 PGP000050 |
Graff RE et al. Nat Commun (2021)
 Reported Trait: Endometrial cancer OR: 1.19 [1.14, 1.24] — — Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. Results from meta-analysis of GERA and UKB
PPM002041 PGS000075
(CC_Endo)
 PSS001014|
European Ancestry|
212,156 individuals
 PGP000186 |
Kachuri L et al. Nat Commun (2020)
|Ext.		 Reported Trait: Incident endometrial cancer HR: 1.19 [1.1, 1.29] AUROC: 0.755
C-index: 0.749 (0.011)		 — Age at assessment, family history of cancer, genotyping array, PCs(1-15), parity ( ≥1 live birth vs. none), age at menarche, body mass index, Menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use (never used (0) vs. <20 years vs. ≥20 years), C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years.
PPM017170 PGS000075
(CC_Endo)
 PSS010152|
European Ancestry|
494 individuals
 PGP000443 |
Byrne S et al. Int J Epidemiol (2023)
|Ext.		 Reported Trait: Uterine cancer HR: 1.31 [1.2, 1.44] — — age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates —
PPM000202 PGS000082
(CC_Ovary)
 PSS000121|
European Ancestry|
220,909 individuals
 PGP000050 |
Graff RE et al. Nat Commun (2021)
 Reported Trait: Ovarian cancer OR: 1.14 [1.08, 1.2] — — Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. Results from meta-analysis of GERA and UKB
PPM002048 PGS000082
(CC_Ovary)
 PSS001021|
European Ancestry|
211,958 individuals
 PGP000186 |
Kachuri L et al. Nat Commun (2020)
|Ext.		 Reported Trait: Incident ovarian cancer HR: 1.13 [1.04, 1.24] AUROC: 0.656
C-index: 0.655 (0.015)		 — Age at assessment, family history of breast cancer, genotyping array, PCs(1-15), parity ( ≥1 live birth vs. none), body mass index, Menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use (never used (0) vs. <20 years vs. ≥20 years), BMI*menopausal status C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years.
PPM017174 PGS000082
(CC_Ovary)
 PSS010149|
European Ancestry|
315 individuals
 PGP000443 |
Byrne S et al. Int J Epidemiol (2023)
|Ext.		 Reported Trait: Ovarian cancer HR: 1.09 [0.97, 1.21] — — age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates —
PPM000489 PGS000158
(cGRS_Ovarian)
 PSS000278|
European Ancestry|
7,551 individuals
 PGP000075 |
Shi Z et al. Cancer Med (2019)
 Reported Trait: Ovarian cancer — — Odds Ratio (OR; high vs. average risk groups): 1.63 [1.3, 2.06] — —
PPM000478 PGS000158
(cGRS_Ovarian)
 PSS000278|
European Ancestry|
7,551 individuals
 PGP000075 |
Shi Z et al. Cancer Med (2019)
 Reported Trait: Ovarian cancer — — Mean realative risk: 1.12 [1.08, 1.16]
Wilcoxon test (case vs. control) p-value: 0.00015		 — —
PPM001030 PGS000351
(PRS_EOC)
 PSS000524|
European Ancestry|
18,935 individuals
 PGP000117 |
Barnes DR et al. Genet Med (2020)
 Reported Trait: Ovarian cancer in BRCA1 carriers HR: 1.31 [1.24, 1.39] — — birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives —
PPM001031 PGS000351
(PRS_EOC)
 PSS000528|
European Ancestry|
12,339 individuals
 PGP000117 |
Barnes DR et al. Genet Med (2020)
 Reported Trait: Ovarian cancer in BRCA2 carriers HR: 1.42 [1.28, 1.58] — — birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives —
PPM001032 PGS000352
(PRS_HGS)
 PSS000524|
European Ancestry|
18,935 individuals
 PGP000117 |
Barnes DR et al. Genet Med (2020)
 Reported Trait: Ovarian cancer in BRCA1 carriers HR: 1.32 [1.25, 1.4] — — birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives —
PPM001033 PGS000352
(PRS_HGS)
 PSS000528|
European Ancestry|
12,339 individuals
 PGP000117 |
Barnes DR et al. Genet Med (2020)
 Reported Trait: Ovarian cancer in BRCA2 carriers HR: 1.43 [1.29, 1.59] — — birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives —
PPM001036 PGS000352
(PRS_HGS)
 PSS000530|
European Ancestry|
3,152 individuals
 PGP000117 |
Barnes DR et al. Genet Med (2020)
 Reported Trait: Incident ovarian cancer in BRCA1 carriers HR: 1.28 [1.06, 1.55] — — family history of the appropriate cancer in first- and second-degree relatives —
PPM001037 PGS000352
(PRS_HGS)
 PSS000532|
European Ancestry|
2,495 individuals
 PGP000117 |
Barnes DR et al. Genet Med (2020)
 Reported Trait: Incident ovarian cancer in BRCA2 carriers HR: 1.45 [1.13, 1.86] — — family history of the appropriate cancer in first- and second-degree relatives —
PPM001226 PGS000541
(PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_P_5e-08_UKB_20200608)
 PSS000571|
European Ancestry|
6,987 individuals
 PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
 Reported Trait: Malignant neoplasm of uterus OR: 1.311 [1.209, 1.422]
β: 0.271 (0.0415)		 AUROC: 0.576 [0.553, 0.6] Nagelkerke's Pseudo-R²: 0.0133
Brier score: 0.082
Odds Ratio (OR, top 1% vs. Rest): 2.12 [1.17, 3.84]		 age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_P_5e-08_UKB_20200608
PPM001227 PGS000542
(PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_PT_UKB_20200608)
 PSS000571|
European Ancestry|
6,987 individuals
 PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
 Reported Trait: Malignant neoplasm of uterus OR: 1.302 [1.2, 1.413]
β: 0.264 (0.0416)		 AUROC: 0.572 [0.549, 0.596] Nagelkerke's Pseudo-R²: 0.0126
Brier score: 0.082
Odds Ratio (OR, top 1% vs. Rest): 2.6 [1.5, 4.51]		 age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE182_GWAS-Catalog-r2019-05-03-X182_PT_UKB_20200608
PPM001654 PGS000724
(PRS_Ovary)
 PSS000858|
European Ancestry|
400,812 individuals
 PGP000135 |
Jia G et al. JNCI Cancer Spectr (2020)
 Reported Trait: Incident epithelial ovarian cancer — AUROC: 0.568 [0.537, 0.598] — Genotyping array —
PPM002055 PGS000784
(CC_Cervix_IV)
 PSS001012|
European Ancestry|
211,795 individuals
 PGP000186 |
Kachuri L et al. Nat Commun (2020)
 Reported Trait: Incident cervical cancer HR: 1.21 [1.07, 1.35] AUROC: 0.745
C-index: 0.749 (0.017)		 R²: 0.437 Age at assessment, genotyping array, PCs(1-15), parity ( ≥1 live birth vs. none), oral contraceptive use (never used (0) vs. <20 years vs. ≥20 years), cigarette pack-years C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years.
PPM002057 PGS000786
(CC_Endo_IV)
 PSS001014|
European Ancestry|
212,156 individuals
 PGP000186 |
Kachuri L et al. Nat Commun (2020)
 Reported Trait: Incident endometrial cancer HR: 1.18 [1.09, 1.27] AUROC: 0.754
C-index: 0.749 (0.011)		 R²: 0.486 Age at assessment, family history of cancer, genotyping array, PCs(1-15), parity ( ≥1 live birth vs. none), age at menarche, body mass index, Menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use (never used (0) vs. <20 years vs. ≥20 years), C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years.
PPM002064 PGS000793
(CC_Ovary_IV)
 PSS001021|
European Ancestry|
211,958 individuals
 PGP000186 |
Kachuri L et al. Nat Commun (2020)
 Reported Trait: Incident ovarian cancer HR: 1.2 [1.1, 1.32] AUROC: 0.66
C-index: 0.654 (0.015)		 R²: 0.193 Age at assessment, family history of breast cancer, genotyping array, PCs(1-15), parity ( ≥1 live birth vs. none), body mass index, Menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use (never used (0) vs. <20 years vs. ≥20 years), BMI*menopausal status C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years.
PPM008992 PGS001299
(GBE_cancer1041)
 PSS007631|
African Ancestry|
6,497 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: Cervical cancer — AUROC: 0.81923 [0.77827, 0.86018] R²: 0.1174
Incremental AUROC (full-covars): -0.00507
PGS R2 (no covariates): 0.00206
PGS AUROC (no covariates): 0.46736 [0.35923, 0.57549]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008993 PGS001299
(GBE_cancer1041)
 PSS007632|
East Asian Ancestry|
1,704 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: Cervical cancer — AUROC: 0.91431 [0.84118, 0.98744] R²: 0.22017
Incremental AUROC (full-covars): 0.00128
PGS R2 (no covariates): 0.0
PGS AUROC (no covariates): 0.52896 [0.28465, 0.77326]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008994 PGS001299
(GBE_cancer1041)
 PSS007633|
European Ancestry|
24,905 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: Cervical cancer — AUROC: 0.76761 [0.74661, 0.7886] R²: 0.11284
Incremental AUROC (full-covars): 0.00676
PGS R2 (no covariates): 0.00263
PGS AUROC (no covariates): 0.55215 [0.51478, 0.58952]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008995 PGS001299
(GBE_cancer1041)
 PSS007634|
South Asian Ancestry|
7,831 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: Cervical cancer — AUROC: 0.83945 [0.77567, 0.90324] R²: 0.13265
Incremental AUROC (full-covars): -0.00075
PGS R2 (no covariates): 0.00058
PGS AUROC (no covariates): 0.46169 [0.30956, 0.61382]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM008996 PGS001299
(GBE_cancer1041)
 PSS007635|
European Ancestry|
67,425 individuals
 PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
 Reported Trait: Cervical cancer — AUROC: 0.7705 [0.75816, 0.78284] R²: 0.11652
Incremental AUROC (full-covars): 0.00962
PGS R2 (no covariates): 0.00294
PGS AUROC (no covariates): 0.54769 [0.52291, 0.57247]		 age, sex, UKB array type, Genotype PCs Full Model & PGS R2 is estimated using Nagelkerke's method
PPM009299 PGS001795
(1kgeur_gbmi_leaveUKBBout_UtC_pst_eff_a1_b0.5_phiauto)
 PSS007718|
European Ancestry|
170,276 individuals
 PGP000262 |
Wang Y et al. Cell Genom (2023)
 Reported Trait: Uterine cancer — AUROC: 0.66 Nagelkerke's R2 (covariates regressed out): 0.00195 sex,age,age2,age*sex,age^2*sex, 20PCs —
PPM016269 PGS002250
(PRS_S4)
 PSS010091|
European Ancestry|
198,758 individuals
 PGP000277 |
Dareng EO et al. Eur J Hum Genet (2022)
 Reported Trait: Epithelial non-mucinous ovarian cancer OR: 1.38 [1.28, 1.48] AUROC: 0.588 — — —
PPM016270 PGS002250
(PRS_S4)
 PSS010087|
European Ancestry|
18,915 individuals
 PGP000277 |
Dareng EO et al. Eur J Hum Genet (2022)
 Reported Trait: Epithelial non-mucinous ovarian cancer in BRCA1 carriers HR: 1.36 [1.29, 1.43] AUROC: 0.592 — — —
PPM016271 PGS002250
(PRS_S4)
 PSS010088|
European Ancestry|
12,337 individuals
 PGP000277 |
Dareng EO et al. Eur J Hum Genet (2022)
 Reported Trait: Epithelial non-mucinous ovarian cancer in BRCA2 carriers HR: 1.49 [1.35, 1.64] AUROC: 0.624 — — —
PPM016272 PGS002250
(PRS_S4)
 PSS010090|
East Asian Ancestry|
7,669 individuals
 PGP000277 |
Dareng EO et al. Eur J Hum Genet (2022)
 Reported Trait: Epithelial non-mucinous ovarian cancer OR: 1.14 [1.08, 1.19] AUROC: 0.538 — — —
PPM016273 PGS002250
(PRS_S4)
 PSS010089|
African Ancestry|
1,072 individuals
 PGP000277 |
Dareng EO et al. Eur J Hum Genet (2022)
 Reported Trait: Epithelial non-mucinous ovarian cancer OR: 1.38 [1.21, 1.58] AUROC: 0.593 — — —
PPM013029 PGS002300
(PRS19_endometrial)
 PSS009660|
European Ancestry|
629 individuals
 PGP000328 |
Choi J et al. Int J Cancer (2020)
 Reported Trait: Endometrial cancer — AUROC: 0.64 [0.61, 0.67] — — —
PPM013037 PGS002300
(PRS19_endometrial)
 PSS009660|
European Ancestry|
629 individuals
 PGP000328 |
Choi J et al. Int J Cancer (2020)
 Reported Trait: Endometrial cancer — — Hazard ratio (HR top 5% vs average): 1.34 [0.96, 1.88] Age, birth cohort, genotyping array, top 10 PCs for ancestry and sex (for nonsex specific cancer only) —
PPM014832 PGS002735
(PRS19)
 PSS009907|
European Ancestry|
118,636 individuals
 PGP000344 |
Bafligil C et al. Genet Med (2022)
 Reported Trait: Risk of endometrial cancer — AUROC: 0.56 [0.54, 0.57] Odds ratio (OR, third vs first tertile): 1.55 [1.37, 1.74] — —
PPM014835 PGS002735
(PRS19)
 PSS009907|
European Ancestry|
118,636 individuals
 PGP000344 |
Bafligil C et al. Genet Med (2022)
 Reported Trait: Risk of endometrial cancer HR: 0.2 [0.15, 0.25] — — BMI —
PPM014833 PGS002736
(PRS24)
 PSS009907|
European Ancestry|
118,636 individuals
 PGP000344 |
Bafligil C et al. Genet Med (2022)
 Reported Trait: Risk of endometrial cancer — AUROC: 0.53 [0.52, 0.54] Odds ratio (OR, third vs first tertile): 1.27 [1.13, 1.43] — —
PPM014836 PGS002736
(PRS24)
 PSS009907|
European Ancestry|
118,636 individuals
 PGP000344 |
Bafligil C et al. Genet Med (2022)
 Reported Trait: Risk of endometrial cancer HR: 0.11 [0.07, 0.16] — — BMI —
PPM014834 PGS002737
(PRS72)
 PSS009907|
European Ancestry|
118,636 individuals
 PGP000344 |
Bafligil C et al. Genet Med (2022)
 Reported Trait: Risk of endometrial cancer — AUROC: 0.54 [0.52, 0.55] Odds ratio (OR, third vs first tertile): 1.32 [1.17, 1.48] — —
PPM014837 PGS002737
(PRS72)
 PSS009907|
European Ancestry|
118,636 individuals
 PGP000344 |
Bafligil C et al. Genet Med (2022)
 Reported Trait: Risk of endometrial cancer HR: 0.13 [0.08, 0.18] — — BMI —
PPM016256 PGS003381
(best_UCEC)
 PSS010086|
European Ancestry|
144,479 individuals
 PGP000413 |
Namba S et al. Cancer Res (2022)
 Reported Trait: uterine endometrial carcinoma — AUROC: 0.761 R²: 0.11 age, top 20 genetic principal components —
PPM016260 PGS003385
(best_OV)
 PSS010083|
European Ancestry|
143,259 individuals
 PGP000413 |
Namba S et al. Cancer Res (2022)
 Reported Trait: ovarian serous carcinoma — AUROC: 0.717 R²: 0.0142 age, top 20 genetic principal components —
PPM016264 PGS003389
(best_CESC)
 PSS010075|
European Ancestry|
144,374 individuals
 PGP000413 |
Namba S et al. Cancer Res (2022)
 Reported Trait: cervical cancer — AUROC: 0.563 R²: 0.00158 age, top 20 genetic principal components —
PPM016274 PGS003394
(PRS_Stepwise)
 PSS010091|
European Ancestry|
198,758 individuals
 PGP000277 |
Dareng EO et al. Eur J Hum Genet (2022)
 Reported Trait: Epithelial non-mucinous ovarian cancer OR: 1.39 [1.29, 1.5] AUROC: 0.595 — — —
PPM016275 PGS003394
(PRS_Stepwise)
 PSS010090|
East Asian Ancestry|
7,669 individuals
 PGP000277 |
Dareng EO et al. Eur J Hum Genet (2022)
 Reported Trait: Epithelial non-mucinous ovarian cancer OR: 1.17 [1.11, 1.23] AUROC: 0.542 — — —
PPM017029 PGS003394
(PRS_Stepwise)
 PSS010098|
European Ancestry|
189,171 individuals
 PGP000417 |
Dite GS et al. Eur J Cancer Prev (2022)
|Ext.		 Reported Trait: 10-year ovarian cancer risks — C-index: 0.623 [0.603, 0.642] — — —
PPM016276 PGS003394
(PRS_Stepwise)
 PSS010089|
African Ancestry|
1,072 individuals
 PGP000277 |
Dareng EO et al. Eur J Hum Genet (2022)
 Reported Trait: Epithelial non-mucinous ovarian cancer OR: 1.37 [1.2, 1.56] AUROC: 0.594 — — —
PPM017102 PGS003428
(Ldpred_CC_170223)
 PSS010125|
European Ancestry|
128,113 individuals
 PGP000435 |
Koel M et al. Hum Mol Genet (2023)
 Reported Trait: Incident cervical cancer HR: 1.33 (0.069) C-index: 0.613 — age, smoking —
PPM018496 PGS003740
(PRS16_CU)
 PSS010989|
European Ancestry|
372 individuals
 PGP000470 |
Xin J et al. EBioMedicine (2023)
 Reported Trait: Corpus Uteri OR: 1.38 [1.2, 1.58] — — — —
PPM018497 PGS003741
(PRS28_OC)
 PSS010991|
European Ancestry|
501 individuals
 PGP000470 |
Xin J et al. EBioMedicine (2023)
 Reported Trait: Ovarian cancer OR: 1.15 [1.04, 1.28] — — — —
PPM018518 PGS003754
(PRS22_OCstepwise)
 PSS011005|
Multi-ancestry (including European)|
11,135 individuals
 PGP000474 |
Hurwitz LM et al. JAMA Netw Open (2023)
 Reported Trait: Nonmucinous Epithelial Ovarian Cancer x aspirin use interaction — — Odds ratio (OR, <median): 0.85 [0.7, 1.02]
Odds ratio (OR, >=median): 0.86 [0.74, 1.01]		 — —
PPM020301 PGS004244
(PRS16_endometrium)
 PSS011328|
European Ancestry|
133,830 individuals
 PGP000542 |
Kim ES et al. NPJ Precis Oncol (2023)
 Reported Trait: Endometrial cancer HR: 1.25 [1.14, 1.36] — — first 10 genetic principal components —
PPM020306 PGS004249
(PRS25_ovary)
 PSS011328|
European Ancestry|
133,830 individuals
 PGP000542 |
Kim ES et al. NPJ Precis Oncol (2023)
 Reported Trait: Ovarian cancer HR: 1.16 [1.03, 1.31] — — first 10 genetic principal components —
PPM020877 PGS004692
(ovarian_cancer)
 PSS011436|
European Ancestry|
22,025 individuals
 PGP000596 |
Hu J et al. JNCI Cancer Spectr (2024)
 Reported Trait: Ovarian cancer — AUROC: 0.5298 — — —
PPM022170 PGS005086
(PGS64518_OC)
 PSS011825|
East Asian Ancestry|
61,457 individuals
 PGP000680 |
Barnes DR et al. NPJ Genom Med (2025)
 Reported Trait: Epithelial ovarian cancer OR: 1.12 [1.05, 1.2] — — — —
PPM022166 PGS005086
(PGS64518_OC)
 PSS011826|
European Ancestry|
245,377 individuals
 PGP000680 |
Barnes DR et al. NPJ Genom Med (2025)
 Reported Trait: Epithelial ovarian cancer OR: 1.46 [1.37, 1.54] AUROC: 0.607 [0.59, 0.623] — — —
PPM022167 PGS005087
(PGS5957_OC)
 PSS011826|
European Ancestry|
245,377 individuals
 PGP000680 |
Barnes DR et al. NPJ Genom Med (2025)
 Reported Trait: Epithelial ovarian cancer OR: 1.45 AUROC: 0.603 — — —
PPM022171 PGS005087
(PGS5957_OC)
 PSS011825|
East Asian Ancestry|
61,457 individuals
 PGP000680 |
Barnes DR et al. NPJ Genom Med (2025)
 Reported Trait: Epithelial ovarian cancer OR: 1.14 — — — —
PPM022168 PGS005088
(PGS3448_OC)
 PSS011826|
European Ancestry|
245,377 individuals
 PGP000680 |
Barnes DR et al. NPJ Genom Med (2025)
 Reported Trait: Epithelial ovarian cancer OR: 1.45 AUROC: 0.604 — — —
PPM022172 PGS005088
(PGS3448_OC)
 PSS011825|
East Asian Ancestry|
61,457 individuals
 PGP000680 |
Barnes DR et al. NPJ Genom Med (2025)
 Reported Trait: Epithelial ovarian cancer OR: 1.14 — — — —
PPM022169 PGS005089
(PGS400_OC)
 PSS011826|
European Ancestry|
245,377 individuals
 PGP000680 |
Barnes DR et al. NPJ Genom Med (2025)
 Reported Trait: Epithelial ovarian cancer OR: 1.43 [1.35, 1.52] AUROC: 0.603 — — —
PPM022173 PGS005089
(PGS400_OC)
 PSS011825|
East Asian Ancestry|
61,457 individuals
 PGP000680 |
Barnes DR et al. NPJ Genom Med (2025)
 Reported Trait: Epithelial ovarian cancer OR: 1.13 — — — —
PPM022403 PGS005165
(PRS-CC)
 PSS011943|
East Asian Ancestry|
57,359 individuals
 PGP000711 |
Zhu M et al. PLoS Med (2025)
 Reported Trait: Cervical Cancer HR: 1.2 [1.06, 1.36]
β: 0.182		 C-index: 0.566 — Age,Sex (if applicable),Region,Top 10 genetic ancestry principal components The HR and C-index values were derived from Cox proportional hazards regression models.
PPM022404 PGS005166
(PRS-OC)
 PSS011944|
East Asian Ancestry|
57,359 individuals
 PGP000711 |
Zhu M et al. PLoS Med (2025)
 Reported Trait: Ovarian Cancer HR: 1.25 [1.02, 1.52]
β: 0.223		 C-index: 0.579 — Age,Sex (if applicable),Region,Top 10 genetic ancestry principal components The HR and C-index values were derived from Cox proportional hazards regression models.
PPM036722 PGS018540
(TPMI_180_Lassosum2)
 PSS012453|
East Asian Ancestry|
8,290 individuals
 PGP000835 |
Chen HH et al. Nature (2025)
 Reported Trait: Cervical cancer and dysplasia — AUROC: 0.71423 R²: 0.10406 sex, age, array, PCs 1-10 —
PPM036723 PGS018541
(TPMI_180_LDpred2)
 PSS012452|
East Asian Ancestry|
8,290 individuals
 PGP000835 |
Chen HH et al. Nature (2025)
 Reported Trait: Cervical cancer and dysplasia — AUROC: 0.71373 R²: 0.10361 sex, age, array, PCs 1-10 —
PPM036724 PGS018542
(TPMI_180_MegaPRS)
 PSS012454|
East Asian Ancestry|
8,290 individuals
 PGP000835 |
Chen HH et al. Nature (2025)
 Reported Trait: Cervical cancer and dysplasia — AUROC: 0.71362 R²: 0.10344 sex, age, array, PCs 1-10 —
PPM036725 PGS018543
(TPMI_180_PRS-CS)
 PSS012455|
East Asian Ancestry|
8,290 individuals
 PGP000835 |
Chen HH et al. Nature (2025)
 Reported Trait: Cervical cancer and dysplasia — AUROC: 0.7135 R²: 0.10346 sex, age, array, PCs 1-10 —
PPM036726 PGS018544
(TPMI_180_SBayesR)
 PSS012456|
East Asian Ancestry|
8,290 individuals
 PGP000835 |
Chen HH et al. Nature (2025)
 Reported Trait: Cervical cancer and dysplasia — AUROC: 0.71409 R²: 0.10359 sex, age, array, PCs 1-10 —
PPM036727 PGS018545
(TPMI_180.1_Lassosum2)
 PSS012443|
East Asian Ancestry|
8,044 individuals
 PGP000835 |
Chen HH et al. Nature (2025)
 Reported Trait: Cervical cancer — AUROC: 0.67978 R²: 0.02097 sex, age, array, PCs 1-10 —
PPM036728 PGS018546
(TPMI_180.1_LDpred2)
 PSS012442|
East Asian Ancestry|
8,044 individuals
 PGP000835 |
Chen HH et al. Nature (2025)
 Reported Trait: Cervical cancer — AUROC: 0.67992 R²: 0.02138 sex, age, array, PCs 1-10 —
PPM036729 PGS018547
(TPMI_180.1_MegaPRS)
 PSS012444|
East Asian Ancestry|
8,044 individuals
 PGP000835 |
Chen HH et al. Nature (2025)
 Reported Trait: Cervical cancer — AUROC: 0.67784 R²: 0.02043 sex, age, array, PCs 1-10 —
PPM036730 PGS018548
(TPMI_180.1_PRS-CS)
 PSS012445|
East Asian Ancestry|
8,044 individuals
 PGP000835 |
Chen HH et al. Nature (2025)
 Reported Trait: Cervical cancer — AUROC: 0.68 R²: 0.02133 sex, age, array, PCs 1-10 —
PPM036731 PGS018549
(TPMI_180.1_SBayesR)
 PSS012446|
East Asian Ancestry|
8,044 individuals
 PGP000835 |
Chen HH et al. Nature (2025)
 Reported Trait: Cervical cancer — AUROC: 0.68346 R²: 0.02179 sex, age, array, PCs 1-10 —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000121 Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 27040 —
[
  • 1,261 cases
  • , 219,648 controls
]
,
0.0 % Male samples
 — European — GERA, UKB —
PSS011825 — —
[
  • 843 cases
  • , 60,614 controls
]
,
0.0 % Male samples
 — East Asian
(Japanese)		 — BBJ —
PSS011826 — —
[
  • 848 cases
  • , 244,529 controls
]
,
0.0 % Male samples
 — European
(British)		 — UKB —
PSS000571 PheCode:182; ICD9:179, 182, 182.0, 182.1, 182.8, 233.2; ICD10:C54.0, C54.1, C54.2, C54.3, C54.8, C54.9, C55, D07.0 —
[
  • 634 cases
  • , 6,353 controls
]
 — European — UKB —
PSS010989 — — 372 individuals Mean = 64.72 years European — TCGA —
PSS007631 — —
[
  • 28 cases
  • , 6,469 controls
]
 — African unspecified — UKB —
PSS007632 — —
[
  • 6 cases
  • , 1,698 controls
]
 — East Asian — UKB —
PSS007633 — —
[
  • 231 cases
  • , 24,674 controls
]
 — European non-white British ancestry UKB —
PSS007634 — —
[
  • 13 cases
  • , 7,818 controls
]
 — South Asian — UKB —
PSS007635 — —
[
  • 561 cases
  • , 66,864 controls
]
 — European white British ancestry UKB Testing cohort (heldout set)
PSS010991 — — 501 individuals Mean = 60.09 years European — TCGA —
PSS011328 — — 133,830 individuals,
0.0 % Male samples
 — European
(British)		 — UKB —
PSS011436 — —
[
  • 110 cases
  • , 21,915 controls
]
,
0.0 % Male samples
 — European — UKB —
PSS012442 180.0, 180.1, 180.8, 180.9, V10.41,C53 —
[
  • 158 cases
  • , 7,886 controls
]
,
0.0 % Male samples
 — East Asian
(Han Chinese)		 — TPMI —
PSS012443 180.0, 180.1, 180.8, 180.9, V10.41,C53 —
[
  • 158 cases
  • , 7,886 controls
]
,
0.0 % Male samples
 — East Asian
(Han Chinese)		 — TPMI —
PSS012444 180.0, 180.1, 180.8, 180.9, V10.41,C53 —
[
  • 158 cases
  • , 7,886 controls
]
,
0.0 % Male samples
 — East Asian
(Han Chinese)		 — TPMI —
PSS012445 180.0, 180.1, 180.8, 180.9, V10.41,C53 —
[
  • 158 cases
  • , 7,886 controls
]
,
0.0 % Male samples
 — East Asian
(Han Chinese)		 — TPMI —
PSS012446 180.0, 180.1, 180.8, 180.9, V10.41,C53 —
[
  • 158 cases
  • , 7,886 controls
]
,
0.0 % Male samples
 — East Asian
(Han Chinese)		 — TPMI —
PSS011943 ICD-10: C53 Median = 11.33 years
Range = [10.18, 12.26] years
[
  • 237 cases
  • , 57,122 controls
]
,
0.0 % Male samples
 Mean = 53.69 years
Sd = 11.01 years		 East Asian
(Chinese)		 — CKB —
PSS011944 ICD-10: C56 Median = 11.33 years
Range = [10.18, 12.26] years
[
  • 96 cases
  • , 57,263 controls
]
,
0.0 % Male samples
 Mean = 53.69 years
Sd = 11.01 years		 East Asian
(Chinese)		 — CKB —
PSS012453 180, 233.1, 622.1, V10.41,C53, D06, N87 —
[
  • 404 cases
  • , 7,886 controls
]
,
0.0 % Male samples
 — East Asian
(Han Chinese)		 — TPMI —
PSS012452 180, 233.1, 622.1, V10.41,C53, D06, N87 —
[
  • 404 cases
  • , 7,886 controls
]
,
0.0 % Male samples
 — East Asian
(Han Chinese)		 — TPMI —
PSS012454 180, 233.1, 622.1, V10.41,C53, D06, N87 —
[
  • 404 cases
  • , 7,886 controls
]
,
0.0 % Male samples
 — East Asian
(Han Chinese)		 — TPMI —
PSS011005 — —
[
  • 122 cases
  • , 218 controls
]
 — African American or Afro-Caribbean
(Black)		 — OCAC —
PSS011005 — —
[
  • 3,995 cases
  • , 5,851 controls
]
 — European — OCAC —
PSS010125 C53, D06 —
[
  • 235 cases
  • , 127,878 controls
]
,
0.0 % Male samples
 — European — EB —
PSS011005 — —
[
  • 359 cases
  • , 590 controls
]
 — Not reported — OCAC —
PSS012455 180, 233.1, 622.1, V10.41,C53, D06, N87 —
[
  • 404 cases
  • , 7,886 controls
]
,
0.0 % Male samples
 — East Asian
(Han Chinese)		 — TPMI —
PSS012456 180, 233.1, 622.1, V10.41,C53, D06, N87 —
[
  • 404 cases
  • , 7,886 controls
]
,
0.0 % Male samples
 — East Asian
(Han Chinese)		 — TPMI —
PSS000524 — —
[
  • 2,068 cases
  • , 16,867 controls
]
,
0.0 % Male samples
 — European — 59 cohorts
  • BCFR-AU
  • ,BCFR-NY
  • ,BCFR-PA
  • ,BCFR-UTAH
  • ,BFBOCC
  • ,BMBSA
  • ,BRICOH
  • ,CNIO
  • ,COH
  • ,CONSIT_TEAM
  • ,CopBCS
  • ,DEMOKRITOS
  • ,DFCI
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,Georgetown
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HUVH
  • ,ICO
  • ,IHCC
  • ,INHERIT
  • ,IOVHBOCS
  • ,IPOBCS
  • ,KUMC
  • ,LUHR
  • ,MACBRCA
  • ,MAYO
  • ,MCGILL
  • ,MDACCS
  • ,MODSQUAD
  • ,MSKCC
  • ,MUV
  • ,NC-BCFR
  • ,NCI
  • ,NICCC
  • ,NNPIO
  • ,NRG_ONCOLOGY
  • ,NSUHS
  • ,OCGN
  • ,OFBCR
  • ,OUH
  • ,PiBCS
  • ,SWE-BRCA
  • ,UC
  • ,UCLA
  • ,UCSF
  • ,UKGRFOCR
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,WCRI
  • ,kConFab
 —
PSS000528 — —
[
  • 718 cases
  • , 11,621 controls
]
,
0.0 % Male samples
 — European — 59 cohorts
  • BCFR-AU
  • ,BCFR-NY
  • ,BCFR-PA
  • ,BCFR-UTAH
  • ,BFBOCC
  • ,BMBSA
  • ,BRICOH
  • ,CNIO
  • ,COH
  • ,CONSIT_TEAM
  • ,CopBCS
  • ,DEMOKRITOS
  • ,DFCI
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,Georgetown
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HUVH
  • ,ICO
  • ,IHCC
  • ,INHERIT
  • ,IOVHBOCS
  • ,IPOBCS
  • ,KUMC
  • ,LUHR
  • ,MACBRCA
  • ,MAYO
  • ,MCGILL
  • ,MDACCS
  • ,MODSQUAD
  • ,MSKCC
  • ,MUV
  • ,NC-BCFR
  • ,NCI
  • ,NICCC
  • ,NNPIO
  • ,NRG_ONCOLOGY
  • ,NSUHS
  • ,OCGN
  • ,OFBCR
  • ,OUH
  • ,PiBCS
  • ,SWE-BRCA
  • ,UC
  • ,UCLA
  • ,UCSF
  • ,UKGRFOCR
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,WCRI
  • ,kConFab
 —
PSS000530 To assess associationss between the PRS and ovarian cancer risk, eligibility was restricted to women who had not been diagnosed with ovarian cancer and had not had RRSO at the time of baselinne questionnaire completion. Carriers diagnosed with invasive ovarian, fallopian tube, or peritoneal cancer during the follow-up were considered affected. —
[
  • 108 cases
  • , 3,044 controls
]
,
0.0 % Male samples
 — European — 61 cohorts
  • BCFR
  • ,BCFR-AU
  • ,BCFR-NY
  • ,BCFR-PA
  • ,BCFR-UTAH
  • ,BFBOCC
  • ,BMBSA
  • ,BRICOH
  • ,CNIO
  • ,COH
  • ,CONSIT_TEAM
  • ,CopBCS
  • ,DEMOKRITOS
  • ,DFCI
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,Georgetown
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HUVH
  • ,IBCCS
  • ,ICO
  • ,IHCC
  • ,INHERIT
  • ,IOVHBOCS
  • ,IPOBCS
  • ,KUMC
  • ,LUHR
  • ,MACBRCA
  • ,MAYO
  • ,MCGILL
  • ,MDACCS
  • ,MODSQUAD
  • ,MSKCC
  • ,MUV
  • ,NC-BCFR
  • ,NCI
  • ,NICCC
  • ,NNPIO
  • ,NRG_ONCOLOGY
  • ,NSUHS
  • ,OCGN
  • ,OFBCR
  • ,OUH
  • ,PiBCS
  • ,SWE-BRCA
  • ,UC
  • ,UCLA
  • ,UCSF
  • ,UKGRFOCR
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,WCRI
  • ,kConFab
 —
PSS000532 To assess associationss between the PRS and ovarian cancer risk, eligibility was restricted to women who had not been diagnosed with ovarian cancer and had not had RRSO at the time of baseline questionnaire completion. Carriers diagnosed with invasive ovarian, fallopian tbe, or peritoneal cancer during the follow-up were considered affected. —
[
  • 56 cases
  • , 2,439 controls
]
,
0.0 % Male samples
 — European — 61 cohorts
  • BCFR
  • ,BCFR-AU
  • ,BCFR-NY
  • ,BCFR-PA
  • ,BCFR-UTAH
  • ,BFBOCC
  • ,BMBSA
  • ,BRICOH
  • ,CNIO
  • ,COH
  • ,CONSIT_TEAM
  • ,CopBCS
  • ,DEMOKRITOS
  • ,DFCI
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,Georgetown
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HUVH
  • ,IBCCS
  • ,ICO
  • ,IHCC
  • ,INHERIT
  • ,IOVHBOCS
  • ,IPOBCS
  • ,KUMC
  • ,LUHR
  • ,MACBRCA
  • ,MAYO
  • ,MCGILL
  • ,MDACCS
  • ,MODSQUAD
  • ,MSKCC
  • ,MUV
  • ,NC-BCFR
  • ,NCI
  • ,NICCC
  • ,NNPIO
  • ,NRG_ONCOLOGY
  • ,NSUHS
  • ,OCGN
  • ,OFBCR
  • ,OUH
  • ,PiBCS
  • ,SWE-BRCA
  • ,UC
  • ,UCLA
  • ,UCSF
  • ,UKGRFOCR
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,WCRI
  • ,kConFab
 —
PSS010075 C53 —
[
  • 1,482 cases
  • , 142,892 controls
]
 — European
(British)		 — UKB Controls were samples without any cancer diagnosis or self-reported cancer
PSS000858 Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Ovarian cancer=(ICD-9 = 183.0 or ICD-10 = C56; ICD-O: 8441, 8460, 8462, 8380, 8381, 8470, 8471, 8472, 8473, 8480, 8310, 8140, 8260, 8440, 8450, 9000, 8000, and 8010) Median = 5.8 years
[
  • 358 cases
  • , 400,454 controls
]
,
46.5 % Male samples
 — European — UKB —
PSS007718 — —
[
  • 1,323 cases
  • , 168,952 controls
]
 — European — UKB —
PSS010083 C56, histology was one of the followings: Papillary serous cystadenocarcinoma; Serous cystadenocarcinoma; Serous cystadenoma, borderline malignancy; Serous papillary cystic tumor of borderline malignancy; Serous surface papillary carcinoma —
[
  • 367 cases
  • , 142,892 controls
]
 — European
(British)		 — UKB Controls were samples without any cancer diagnosis or self-reported cancer
PSS010086 C54 —
[
  • 1,587 cases
  • , 142,892 controls
]
 — European
(British)		 — UKB Controls were samples without any cancer diagnosis or self-reported cancer
PSS010149 — —
[
  • 20 cases
  • , 295 controls
]
,
0.0 % Male samples
 — European — UKB —
PSS010152 — —
[
  • 35 cases
  • , 459 controls
]
,
0.0 % Male samples
 — European — UKB —
PSS000278 Primary tumor samples from TCGA —
[
  • 531 cases
  • , 0 controls
]
,
0.0 % Male samples
 Mean = 60.0 years
Sd = 12.0 years		 European — TCGA —
PSS000278 — —
[
  • 0 cases
  • , 7,020 controls
]
,
0.0 % Male samples
 — European — eMERGE —
PSS010087 — —
[
  • 2,053 cases
  • , 16,862 controls
]
,
0.0 % Male samples
 — European — CIMBA —
PSS010091 — —
[
  • 657 cases
  • , 198,101 controls
]
,
0.0 % Male samples
 — European — UKB —
PSS010088 — —
[
  • 717 cases
  • , 11,620 controls
]
,
0.0 % Male samples
 — European — CIMBA —
PSS000072 BRCA1 mutation carriers were followed until the age of ovarian cancer diagnosis, age at risk-reducing salpingo-oophorectomy (RRSO) or age at last observation. Breast cancer diagnosis was not considered as a censoring event in the ovarian cancer analysis —
[
  • 2,462 cases
  • , 12,790 controls
]
,
0.0 % Male samples
 — European Some analyses accounted for samples part of the larger cohort with Ashkenazi Jewish ancestry CIMBA Median censoring age (cases) = 50
PSS010090 — —
[
  • 2,841 cases
  • , 4,828 controls
]
,
0.0 % Male samples
 — East Asian — OCAC —
PSS010089 — —
[
  • 368 cases
  • , 704 controls
]
,
0.0 % Male samples
 — African unspecified — OCAC —
PSS009660 endometrial cancer (ICD-9 = 182 or ICD-10 = C54) — 629 individuals — European — UKB —
PSS000108 Adjudicated endpoint determined from medical notes by an outcome review committee Mean = 11.1 years
IQR = [10.0, 12.0] years
[
  • 750 cases
  • , 1,428 controls
]
,
0.0 % Male samples
 Mean = 63.0 years
Range = [50.0, 74.0] years		 European — UKCTOCS —
PSS000108 Adjudicated endpoint determined from medical notes by an outcome review committee Mean = 11.1 years
IQR = [10.0, 12.0] years
[
  • 489 cases
  • , 1,428 controls
]
,
0.0 % Male samples
 Mean = 63.0 years
Range = [50.0, 74.0] years		 European — UKCTOCS —
PSS001012 Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. —
[
  • 282 cases
  • , 211,513 controls
]
,
0.0 % Male samples
 — European — UKB —
PSS001014 Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. —
[
  • 643 cases
  • , 211,513 controls
]
,
0.0 % Male samples
 — European — UKB —
PSS000114 Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 27020 —
[
  • 2,051 cases
  • , 219,648 controls
]
,
0.0 % Male samples
 — European — GERA, UKB —
PSS009907 — —
[
  • 1,676 cases
  • , 116,960 controls
]
,
0.0 % Male samples
 — European — NR UKB
PSS010098 — — 189,171 individuals,
0.0 % Male samples
 — European — UKB —
PSS000112 Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 27010 —
[
  • 6,568 cases
  • , 219,648 controls
]
,
0.0 % Male samples
 — European — GERA, UKB —
PSS000073 BRCA2 mutation carriers were followed until the age of ovarian cancer diagnosis, age at risk-reducing salpingo-oophorectomy (RRSO) or age at last observation. Breast cancer diagnosis was not considered as a censoring event in the ovarian cancer analysis —
[
  • 631 cases
  • , 7,580 controls
]
,
0.0 % Male samples
 — European Some analyses accounted for samples part of the larger cohort with Ashkenazi Jewish ancestry CIMBA Median censoring age (cases) = 57
PSS001021 Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. —
[
  • 445 cases
  • , 211,513 controls
]
,
0.0 % Male samples
 — European — UKB —